author={Caroline M. Perry and Anthony Markham},
SummaryAbstractPiperacillin/tazobactam is a β-lactam/β-lactamase inhibitor combination with a broad spectrum of antibacterial activity encompassing most Gram-positive and Gram-negative aerobic bacteria and anaerobic bacteria, including many pathogens producing β-lactamases.Evidence from clinical trials in adults has shown that piperacillin/tazobactam, administered in an 8: 1 ratio, is an effective treatment for patients with lower respiratory tract, intra-abdominal, urinary tract… 

Piperacillin–Tazobactum Plus Amikacin Versus Ceftazidime Plus Amikacin as Empirical Therapy for Fever in Neutropenic Patients with Hematological Malignancies

It is recommended that piperacillin–tazobactum + amikacin should be given in febrile neutropenic patients with haematological malignancies.

Hematologic adverse effects induced by piperacillin–tazobactam: a systematic review of case reports

Although part of the patients have clinical symptom, the hematologic adverse drug reactions of piperacillin/tazobactam are easily overlooked or misdiagnosed, and prompt recognition and treatment of the adverseDrug reactions are essential and can hasten recovery regardless of the type of side reactions.

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study

Close monitoring of serum potassium levels, especially upon therapy initiation, is essential to prevent TAH, as hypokalemia mostly occurred in the early days of TZP therapy (median onset time: 4 days).

Relationship between pharmacokinetics and pharmacodynamics of beta-lactams and outcome.

The use of breakpoints to determine the susceptibility of microorganisms was not satisfactory in predicting the outcome for a large number of patients, and dosages can be adjusted according to these parameters, thereby allowing antibiotic treatment to be individualised.

Rapid onset severe thrombocytopenia following reexposure to piperacillin-tazobactam: report of two cases and review of the literature

Two cases in whom severe and rapid development of thrombocytopenia has occurred subsequent to administration of piperacillin-tazobactam with a prior history of recent exposure to the drug are presented.

Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Com

The protocol of a clinical study aimed at the characterization of the pharmacokinetics of piperacillin and tazobactam and its association with the concentrations of inflammatory markers and adrenal steroids during CAP therapy will be investigated in up to 40 critically ill patients.

Piperacillin/tazobactam-induced coagulopathy in a patient through a vitamin K-dependent mechanism

It is concluded that PTZ can induce coagulopathy through a vitamin K-dependent mechanism and, to the authors' knowledge, this is the first case report to suggest that mechanism.



Piperacillin/tazobactam: a critical review of the evolving clinical literature.

  • W. SandersC. Sanders
  • Biology, Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1996
Piperacillin/tazobactam may be especially useful for the treatment of infections that are likely to be polymicrobial or to be due to any one of an array of aerobic or anaerobic bacteria; this agent may also be useful in situations where organisms with plasmid-mediated beta-lactamases have become problematic.

Piperacillin/tazobactam in the treatment of polymicrobial infections

  • S. Gorbach
  • Biology, Medicine
    Intensive Care Medicine
  • 2005
P Piperacillin/tazobactam, a new combination broad-spectrum antibiotic and potent β-lactamase inhibitor, can be used for the treatment of infections caused by piperacillin-sensitive microorganisms as well as β- lactamases-producing, piperACillin-resistant organisms.

Efficacy and safety of piperacillin/tazobactam in intra-abdominal infections.

  • K. VestweberE. Grundel
  • Medicine, Biology
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement
  • 1994
Piperacillin/tazobactam was extremely active against the Gram-negative aerobic, Gram-positive aerobic, and anaerobic bacteria isolated in this trial and was well tolerated and the side effects were minimal.

Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.

Piperacillin/tazobactam appears to be more effective than ticarcillin/clavulanate in this patient population and is generally well tolerated.

[A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].

The results suggest that TAZ/PIPC administered at a dose of 2.5 g (titer) twice a day is more useful than PIPCadministered at a doses of 1.8:1, with significantly better eradication of bacteria as well in the treatment of bacterial pneumonia.

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

Piperacillin-tazobactam is effective and safe for the treatment of intra-abdominal infections and the microorganisms isolated were eradicated in similar proportions in the two patient groups.

Therapy of soft tissue infections with piperacillin/tazobactam.

The efficacy and safety of piperacillin in combination with the beta-lactamase inhibitor tazobactam were assessed in an open, multi-centre study of hospitalized patients with skin and soft tissue

Piperacillin and Tazobactam Versus Clindamycin and Gentamicin in the Treatment of Hospitalized Women With Pelvic Infection

The combination of piperacillin and tazobactam is an effective and well-tolerated antibiotic regimen for the treatment of infections of the upper genital tract in women.

Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.

  • L. LiebowitzK. Klugman
  • Medicine, Biology
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • 1996
The in vitro spectrum of activity of piperacillin/tazobactam against the majority of isolates was comparable to those of the other new agents tested.